Tri­umvi­ra snags $55M Se­ries A to guide TAC tech­nol­o­gy to the clin­ic

Tri­umvi­ra Im­muno­log­ics wants to bring its T-cell anti­gen cou­pler (TAC) tech­nol­o­gy to the clin­ic ear­ly next year, and it plans on rid­ing a $55 mil­lion Se­ries A to get there.

The Austin, TX-based biotech an­nounced the com­ple­tion of its fi­nanc­ing round on Thurs­day. And now pres­i­dent and CEO Paul Lam­mers says it’s “all hands on deck” to sub­mit an IND for the com­pa­ny’s HER2-di­rect­ed TAC for sol­id tu­mor pa­tients. Lam­mers hopes the TAC will be ready for hu­man test­ing in late Q1 of 2021.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER